Abbott is a diversified healthcare company operating across four segments: Medical Devices, Diagnostics, Nutritional Products, and Established Pharmaceuticals (EPD). Medical Devices is the largest and fastest-growing segment, anchored by two major franchises. The first is CGM, led by FreeStyle Libre, a wearable sensor that tracks blood glucose continuously for diabetes patients; Libre generates recurring sensor revenue that scales with its installed user base. The second is cardiovascular devices, spanning electrophysiology catheters and mapping systems for AFib ablation, structural heart devices (MitraClip, TriClip, Navitor TAVR), heart failure devices (HeartMate, CardioMEMS), and the Aveir leadless pacemaker. Diagnostics operates on a razor/blade model — Abbott places Alinity instruments at hospitals and labs under long-term contracts, then earns recurring revenue from reagent and test cartridge consumption. Abbott also sells rapid and molecular diagnostics, though COVID testing revenue has been declining. EPD sells branded generic pharmaceuticals across 160+ countries in emerging markets, growing roughly 7-8% annually, with a pipeline of ~15 biosimilars in development. Nutritional Products sells Similac infant formula and adult nutrition brands like Ensure and Glucerna through retail and healthcare channels, though this segment is currently trading price for volume recovery. Abbott's growth strategy centers on sustaining momentum in CGM and EP while re-accelerating slower device categories through innovation. Abbott also agreed to acquire Exact Sciences in late 2025, which would add cancer diagnostics capabilities.